$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032248 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$2.350K	$1.150K	$0.00
YoY Change
Cost Of Revenue	$180.00	$146.00
YoY Change
Gross Profit	$2.170K	$1.005K
YoY Change
Gross Profit Margin	92.34%	87.39%
Selling, General & Admin	$1.429M	$596.5K	$880.8K
YoY Change	62.21%
% of Gross Profit	65836.87%	59351.24%
Research & Development	$197.3K	$319.7K	$1.326M
YoY Change	-85.12%	-3.33%
% of Gross Profit	9089.86%	31815.32%
Depreciation & Amortization	$7.330K	$770.00	$3.180K
YoY Change	130.5%
% of Gross Profit	337.79%	76.62%
Operating Expenses	$1.626M	$977.2K	$2.207M
YoY Change	-26.32%	85.67%
Operating Profit	-$1.624M	-$976.2K
YoY Change		85.48%
Interest Expense	-$50.84K	$889.1K	-$4.357M
YoY Change	-98.83%	556.84%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.675M	-$4.919M	-$6.324M
YoY Change	-73.52%	224.96%
Income Tax	$0.00	$300.00	$1.950K
% Of Pretax Income
Net Earnings	-$1.675M	-$4.919M	-$6.326M
YoY Change	-73.53%	224.98%
Net Earnings / Revenue	-71258.72%	-427778.96%
Basic Earnings Per Share		-$1.17
Diluted Earnings Per Share	-$0.37	-$587.8K	-$4.218M
COMMON SHARES
Basic Shares Outstanding	8.370M shares	4.204M shares
Diluted Shares Outstanding		4.204M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.41M	$13.50M
YoY Change
Cash & Equivalents	$11.40M	$13.50M	$1.361M
Short-Term Investments
Other Short-Term Assets	$531.9K	$541.3K
YoY Change
Inventory	$5.540K	$5.715K
Prepaid Expenses
Receivables	$10.49K	$9.930K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$11.96M	$14.05M	$1.438M
YoY Change	731.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$214.4K	$1.781K	$4.633K
YoY Change	4528.49%
Goodwill
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.000K	$6.000K	$2.500K
YoY Change	140.0%
Total Long-Term Assets	$220.4K	$7.781K	$15.08K
YoY Change	1362.28%
TOTAL ASSETS
Total Short-Term Assets	$11.96M	$14.05M	$1.438M
Total Long-Term Assets	$220.4K	$7.781K	$15.08K
Total Assets	$12.18M	$14.06M	$1.453M
YoY Change	738.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$345.0K	$149.9K	$230.4K
YoY Change	49.75%
Accrued Expenses	$541.9K	$474.0K	$483.5K
YoY Change	12.08%
Deferred Revenue
YoY Change
Short-Term Debt	$251.7K	$815.1K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.139M	$1.464M	$13.04M
YoY Change	-91.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.139M	$1.464M	$13.04M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$1.139M	$1.464M	$13.20M
YoY Change	-91.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.70M	-$35.00M	-$28.51M
YoY Change	28.71%
Common Stock	$58.67K	$58.59K	$18.74K
YoY Change	213.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.04M	$12.60M	-$15.79M
YoY Change
Total Liabilities & Shareholders Equity	$12.18M	$14.06M	$1.453M
YoY Change	738.23%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$1.675M	-$4.919M	-$6.326M
YoY Change	-73.53%	224.98%
Depreciation, Depletion And Amortization	$7.330K	$770.00	$3.180K
YoY Change	130.5%
Cash From Operating Activities	-$1.301M	-$1.760M	-$1.656M
YoY Change	-21.48%
INVESTING ACTIVITIES
Capital Expenditures	$220.0K		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$220.0K		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-563.6K	15.04M	2.789M
YoY Change	-120.2%
NET CHANGE
Cash From Operating Activities	-1.301M	-1.760M	-1.656M
Cash From Investing Activities	-220.0K		0.000
Cash From Financing Activities	-563.6K	15.04M	2.789M
Net Change In Cash	-2.084M	13.28M	1.133M
YoY Change	-283.98%
FREE CASH FLOW
Cash From Operating Activities	-$1.301M	-$1.760M	-$1.656M
Capital Expenditures	$220.0K		$0.00
Free Cash Flow	-$1.521M		-$1.656M
YoY Change	-8.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001712762
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Inventory Net InventoryNet		usd
CY2022Q3	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q3	BIAF	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent		usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q3	BIAF	Paycheck Protection Program Loan Noncurrent PaycheckProtectionProgramLoanNoncurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2021Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Accretion Expense AccretionExpense		usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes		usd
CY2022Q3	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet		usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2022Q3	BIAF	Debt Conversion Term DebtConversionTerm	P5Y
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity File Number EntityFileNumber	001-41463
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	bioAffinity Technologies, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5211056
	dei	Entity Address Address Line1 EntityAddressAddressLine1	22211 W. Interstate 10
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1206
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Antonio
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78257
	dei	City Area Code CityAreaCode	(210)
	dei	Local Phone Number LocalPhoneNumber	698-5334
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8369750	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13497938	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1360638	usd
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9930	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1530	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	5715	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	541323	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	76065	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	14054906	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1438233	usd
CY2021Q4	us-gaap	Deferred Costs DeferredCosts	7942	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1781	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4633	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2500	usd
CY2022Q3	us-gaap	Assets Assets	14062687	usd
CY2021Q4	us-gaap	Assets Assets	1453308	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	149867	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	230407	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	474035	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	483501	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	25168	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1121392	usd
CY2021Q4	BIAF	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	52074	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	490117	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13039525	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	325000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11152151	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1464187	usd
CY2021Q4	BIAF	Paycheck Protection Program Loan Noncurrent PaycheckProtectionProgramLoanNoncurrent	160184	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1464187	usd
CY2021Q4	us-gaap	Liabilities Liabilities	13199709	usd
CY2022Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5296044	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5296044	shares
CY2022Q3	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	0
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	5825648
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4044318	usd
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8369750	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8369750	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2677140	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2677140	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	58588	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	18740	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47532797	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12703896	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34992885	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28513355	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12598500	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14062687	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1453308	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1150	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2457	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	146	usd
	us-gaap	Cost Of Revenue CostOfRevenue	292	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1005	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	949388	usd
	us-gaap	Gross Profit GrossProfit	2165	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	319744	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	330772	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	877674	usd
CY2022Q3	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	60941	usd
CY2021Q3	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	33972	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	141684	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	78241	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	596476	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	161549	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1298409	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	591155	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	977161	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	526293	usd
	us-gaap	Operating Expenses OperatingExpenses	2389481	usd
	us-gaap	Operating Expenses OperatingExpenses	1547070	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-976156	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-526293	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6027414	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4044318	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16065332	usd
CY2022Q3	BIAF	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	7713310	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74900	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4919458	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12598500	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-15072863	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	152837	usd
	us-gaap	Net Income Loss NetIncomeLoss	764269	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-14155757	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-20306	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1513794	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1513794	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-15689857	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6479530	usd
	us-gaap	Net Income Loss NetIncomeLoss	-749525	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2852	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4023	usd
	us-gaap	Accretion Expense AccretionExpense	1972948	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	924099	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	211745	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	132531	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	239200	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	8400	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2387316	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1547070	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	19	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	850	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	24	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	889091	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	135359	usd
	us-gaap	Interest Expense InterestExpense	2435941	usd
	us-gaap	Interest Expense InterestExpense	363828	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	239200	usd
CY2022Q3	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-3053914	usd
CY2021Q3	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-852161	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	924099	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4919158	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1513794	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6477071	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-747575	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2459	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1950	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4919458	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1513794	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6479530	usd
	us-gaap	Net Income Loss NetIncomeLoss	-749525	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4203781	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2675054	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3194765	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2674924	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	132732	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	213942	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	-185	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	217973	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1560072	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16786329	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	79013	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	134277	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	165723	usd
CY2022Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5715	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	502177	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	51760	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-80725	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	68100	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1524	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-269	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	465653	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	363661	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2770209	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1396538	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6027414	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7713310	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74900	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	555148	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	212258	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	31612	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	724000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1345000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	100000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	55651	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14907509	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1557258	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12137300	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	160720	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1360638	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	83108	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13497938	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	243828	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2459	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1950	usd
	us-gaap	Interest Paid Net InterestPaidNet	3945	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4044318	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	16065332	usd
	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	352250	usd
	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes	379665	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse stock split
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35000000.0	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13500000	usd
CY2022Q3	BIAF	Total Assets Percent TotalAssetsPercent	0.96	pure
CY2021Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	55081	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zKgvG3xClZ6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassifications</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	541323	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8834	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4219	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	76065	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	471270	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zSRLp9S8L6S2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the fair value of the Company’s Common Stock used to measure stock-based compensation for options granted to employees and non-employees; the valuation allowance on the Company’s deferred tax assets; and the fair value of the convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1800000	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	8000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5514717	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3182744	shares
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	16765	usd
CY2022Q3	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	61219	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	263631	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	263631	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	261850	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	258998	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1781	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4633	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2900	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	231628	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	277185	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	188524	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	166069	usd
CY2022Q3	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	49630	usd
CY2021Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	39482	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4253	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	765	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	474035	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	483501	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	9405957	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	8781957	usd
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	1185382	usd
CY2022Q3	BIAF	Fair Value Adjustments On Convertible Notes Payables FairValueAdjustmentsOnConvertibleNotesPayables	5422498	usd
CY2021Q4	BIAF	Fair Value Adjustments On Convertible Notes Payables FairValueAdjustmentsOnConvertibleNotesPayables	3555576	usd
CY2022Q3	BIAF	Conversion On Initial Public Offering ConversionOnInitialPublicOffering	14503455	usd
CY2021Q4	BIAF	Conversion On Initial Public Offering ConversionOnInitialPublicOffering	-3555576	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	325000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11152151	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	325000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11152151	usd
CY2021	us-gaap	Fair Value Assets And Liabilities Measured On Recurring Basis Gain Loss Included In Earnings FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings	11152151	usd
CY2022Q3	us-gaap	Convertible Debt ConvertibleDebt	700000	usd
CY2021Q3	us-gaap	Convertible Debt ConvertibleDebt	500000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11152151	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	724000	usd
	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Repayment Of Convertible Notes Payable FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfConvertibleNotesPayable	-100000	usd
	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Discount For Warrant Issued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtDiscountForWarrantIssued	-787566	usd
	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion Of Debt Issuance Costs FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDebtIssuanceCosts	1972948	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	1866922	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3	-325000	usd
	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Convertible Notes Payable FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfConvertibleNotesPayable	-14503455	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	9767461	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	3295000	usd
CY2021	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Discount For Warrant Issued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtDiscountForWarrantIssued	-1665956	usd
CY2021	BIAF	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion Of Debt Issuance Costs FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDebtIssuanceCosts	480574	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-724928	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11152151	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	15000	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	13000	usd
	us-gaap	Payments For Rent PaymentsForRent	41000	usd
	us-gaap	Payments For Rent PaymentsForRent	39000	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse stock split
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8369750	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1100000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	1000000.0	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	211745000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	132531000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	878380	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.20
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	64848	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14282	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.95
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	806392	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	647793	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	787746	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.31
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	647793	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	64848	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	75000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	29279	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.85
CY2022Q3	us-gaap	Share Price SharePrice	4.62
CY2021Q3	us-gaap	Share Price SharePrice	3.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.639	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.881	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	2.20	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.92	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q3	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	Pursuant to the underwriting agreement dated August 31, 2022 (the “Underwriting Agreement”) between the Company and WallachBeth Capital, LLC, as representative of the underwriters (the “Underwriters”), and solely for purposes of covering any over-allotments made in connection with our IPO, we granted the Underwriters an option to purchase up to an additional 192,390 shares of Common Stock at the Offering Price per Unit less $0.02, and/or up to 192,390 Tradeable Warrants at $0.01 per Tradeable Warrant, and/or up to 192,390 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination of additional shares of Common Stock, Tradeable Warrants, and Non-tradeable Warrants representing, in the aggregate, up to 15% of the number of Units sold in the IPO (the “Over-Allotment Option”). The Over-Allotment Option was exercisable for a period of 45 days from the date of our Final Prospectus.
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	400000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2000000.0	usd
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.06	pure
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.20
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25

Files In Submission

Name	View Source	Status
0001493152-22-032248-index-headers.html	Edgar Link	pending
0001493152-22-032248-index.html	Edgar Link	pending
0001493152-22-032248.txt	Edgar Link	pending
0001493152-22-032248-xbrl.zip	Edgar Link	pending
biaf-20220930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
biaf-20220930_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
biaf-20220930_pre.xml	Edgar Link	unprocessable
biaf-20220930_def.xml	Edgar Link	unprocessable
biaf-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2022 Q4 Form 10-Q Financial Statement

#000149315222032248 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2022 Q4 Form 10-Q Financial Statement

#000149315222032248 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf